All NIAID articles
-
NewsExperimental NIH malaria monoclonal antibody protective in Malian children
One injected dose of an experimental malaria monoclonal antibody was 77% effective against malaria disease in children in Mali during the country’s six-month malaria season, according to the results of a mid-stage clinical trial.
-
News Antimicrobial-resistant hospital infections remain at least 12% above pre-pandemic levels, major US study finds
Despite progress in combating antimicrobial resistance (AMR) in the USA since its peak during the COVID-19 pandemic, hospital-acquired AMR infections remain well above pre-pandemic levels, according to a major new study examining AMR before, during, and after the COVID-19 pandemic in 120 US hospitals. Source: NIAID Colorized scanning ...
-
NewsA combination of approved drugs enhances the delivery of anti-bacterial medications to treat tuberculosis
Scientists repurposed approved drugs that they originally tested to normalize blood vessels surrounding tumors to improve drug delivery to cancer cells.
-
NewsClinical trial of HIV vaccine begins in United States and South Africa
A trial of a preventive HIV vaccine candidate has begun enrollment in the United States and South Africa. The Phase 1 trial will evaluate a novel vaccine known as VIR-1388 for its safety and ability to induce an HIV-specific immune response in people. Source: NIAID Transmission electron micrograph ...
-
NewsClinical trial of mRNA universal influenza vaccine candidate begins
A clinical trial of an experimental universal influenza vaccine, H1ssF-3928 mRNA-LNP, has begun enrolling volunteers to test for safety and its ability to induce an immune response.
-
NewsMonoclonal antibody programme targets mucormycosis
Vitalex Biosciences has been awarded an SBIR Phase 2 grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health for VX-01, a monoclonal antibody (mAB) programme targeting the debilitating indication of the fungal disease, mucormycosis.
-
NewsPhase 2 trial of Ebola vaccines yields promising results
An international team of scientists has published the results of a large-scale randomized clinical trial in West Africa which confirms the safety of three vaccine regimens for Ebola and suggests an immune response is induced and maintained for up to 12 months.
